Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda‐Gail Bekker, Flavia Matovu Kiweewa, Katherine Gill et al.|New England Journal of Medicine|2024Cited by 471
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Jason Flamm, Peter Ruane et al.|The Lancet HIV|2021Cited by 91
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender WomenJeanne Marrazzo, Connie Celum, Tao Li et al.|JAMA|2024Cited by 79